Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825659 | 0.87 | HDAC1 (0.56) | HDAC1HDAC6GFERNOS1GRK6 | |
| SCHEMBL19956579 | 0.83 | HDAC1 (0.57) | HDAC1HDAC6NOS1 | |
| SCHEMBL19956623 | 0.81 | HDAC1 (0.42) | HDAC1HDAC6DHFR | |
| SCHEMBL3956722 | 0.79 | LOXL2 (0.47) | HDAC1HDAC6AOC3 | |
| SCHEMBL4829173 | 0.79 | HDAC1 (0.44) | HDAC1HDAC6AOC3 | |
| SCHEMBL5908633 | 0.78 | NOS1 (0.53) | HDAC1HDAC6NOS1 | |
| SCHEMBL4834326 | 0.78 | HDAC1 (0.65) | HDAC1HDAC6 | |
| Bromide SCHEMBL4084010 | 0.78 | LOXL2 (0.46) | HDAC1HDAC6AOC3 | |
| SCHEMBL11926805 | 0.75 | SLC6A3 (0.49) | HDAC1HDAC6 | |
| SCHEMBL19362878 | 0.75 | PTPRB (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | HDAC1 662/4885HDAC6 981/4885GFER 575/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | HDAC1 662/4885HDAC6 981/4885GFER 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.